2.17
+0.0431(+2.02%)
Currency In USD
| Previous Close | 2.13 |
| Open | 2.12 |
| Day High | 2.24 |
| Day Low | 2.12 |
| 52-Week High | 2.73 |
| 52-Week Low | 0.85 |
| Volume | 5.3M |
| Average Volume | 8.96M |
| Market Cap | 656.08M |
| PE | -1.02 |
| EPS | -2.13 |
| Moving Average 50 Days | 2.03 |
| Moving Average 200 Days | 1.5 |
| Change | 0.04 |
If you invested $1000 in Pacific Biosciences of California, Inc. (PACB) 10 years ago, it would be worth $171.89 as of January 14, 2026 at a share price of $2.166. Whereas If you bought $1000 worth of Pacific Biosciences of California, Inc. (PACB) shares 5 years ago, it would be worth $57.42 as of January 14, 2026 at a share price of $2.166.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
PacBio Announces Plans for Collaboration With n-Lorem Foundation and EspeRare to Advance Precision Therapies for Rare Genetic Diseases
GlobeNewswire Inc.
Jan 12, 2026 2:15 PM GMT
The planned collaboration highlights the role of complete genome resolution in scaling n-of-1 therapeutic modelsMENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technolog
PacBio Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
GlobeNewswire Inc.
Jan 12, 2026 2:05 PM GMT
Q4 2025 revenue growth of 14% year-over-year, driven by strong Revio and Vega shipments and record consumables revenueMENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate
PacBio HiFi Adopted as First-Line Sequencing Approach to Investigate Sudden Unexplained Death in Childhood (SUDC)
GlobeNewswire Inc.
Jan 12, 2026 2:05 PM GMT
Trios from 200 families who have lost a child to SUDC to be sequenced on PacBio’s Revio system with SPRQ-Nx chemistry, enabling increased diagnostic yield for grieving familiesMENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PA